DeepMatter signs license agreement with Merck

LONDON, UK: DeepMatter Group, the digital chemistry data and software company, has signed a multiyear database license agreement with Merck, a leading science and technology company, operating across Healthcare, Life Science and Electronics.

Pursuant to the agreement, DeepMatter will licence to the Life Science business sector of Merck certain proprietary data for machine learning-based applications. The terms of the agreement were not disclosed.

“We are delighted to announce an important licensing agreement with Merck, one of the leading companies using digitalisation in healthcare and life sciences to deliver our vision to provide the data that enables all medicines to be made in the best possible way,” said Mark Warne, CEO of DeepMatter.

Merck and Deepmatter will also explore ways to identify, acquire, generate and structure sets of chemical reaction data that can be used to enable scientists to develop new molecules faster and more efficiently which could encompass use of DeepMatter’s SmartChemistry® capabilities.

DeepMatter’s SmartChemistry® platform enables scientists across a range of industries, including pharma, biotech, agri-science, scientific publishers and contract research organisations (CROs), to easily capture, access and exploit the vast amounts of data created in chemical reactions.

DeepMatter integrates its proprietary chemistry data and proprietary software to significantly improve productivity, efficiency, discovery, safety and sustainability of chemical reactions for its customers.

DeepMatter’s SmartChemistry® platform capitalises on the combination of its cloud technology, low cost-sensors, connectivity to laboratory hardware and high-performance computing trends such as artificial intelligence (AI).